Background: Glomerular filtration rate (GFR) estimation is the gold standard for assessment of renal function, although the clinical utility of this test is unclear.
| INTRODUCTION
Accurately assessing renal function can be useful in dogs with suspected kidney disease. Such situations include screening for renal dysfunction as a cause of polyuria and polydipsia in dogs that are non-azotemic, have only a borderline increase in serum creatinine concentration, have isolated increases in novel markers such as symmetric dimethylarginine (SDMA), or have persistently reduced urine concentrating ability. 1 Other indications include monitoring for progression of existing chronic kidney disease (CKD), screening for renal dysfunction in breeds predisposed to hereditary nephropathies, 2 dosage adjustment of renally excreted drugs, and monitoring the effects of chronic administration of potentially nephrotoxic drugs. 3 Glomerular filtration rate (GFR) estimation is the gold standard for assessment of renal function, as it is directly proportional to renal mass. 4 Glomerular filtration rate is estimated by assessing the clearance of a marker of glomerular filtration. 1 Urinary clearance of inulin is the reference method for estimating GFR in humans and dogs. A more Abbreviations: AKI, acute kidney injury; CKD, chronic kidney disease; CRGV, cutaneous and renal glomerular vasculopathy; GFR, glomerular filtration rate; PLN, protein-losing nephropathy; RVC, Royal Veterinary College; SDMA, symmetric dimethylarginine; UCCR, urine cortisol-to-creatinine ratio; USG, urine specific gravity. practical alternative is to measure the plasma/serum clearance of 1 or more of various markers. Markers used to estimate GFR in animals include inulin, exogenous creatinine, radionucleotides, and iohexol. [5] [6] [7] [8] Because of its ease of use, cost, and availability, plasma clearance of iohexol has become 1 of the more widely used markers of GFR in veterinary and human medicine. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Techniques using limited sampling have been used in human and veterinary medicine as a practical means to estimate GFR. When using such techniques, a correction formula must be applied to achieve more accurate approximations of GFR. The most widely used of these, the Brøchner-Mortensen formula, has been extrapolated from human medicine for use in veterinary studies [19] [20] [21] ; however, a systematic review of species differences has not been performed. More recently, Bexfield et al. described a correction formula for estimation of GFR in dogs using a 1-compartmental clearance technique taking dog weight and age into account. 21, 22 Serum creatinine, a surrogate marker of GFR, has largely replaced GFR estimation in clinical practice because of its availability, practicality of measurement, and widespread use in monitoring and staging kidney disease. 23 However, serum creatinine is insensitive to early decline in GFR because of the exponential relationship between serum creatinine concentration and GFR. A further limitation is that reference intervals for creatinine vary with animal size, yet laboratories generally use 1 reference interval for all animals irrespective of their size. Additionally, reference intervals vary between laboratories depending on the method of measuring creatinine. 24 Despite GFR estimation being the gold standard for assessing renal function, it remains infrequently used and data on the widespread clinical utility of GFR estimation in clinical practice are lacking. The aim of this study was to describe the clinical utility of GFR estimation determined by serum iohexol clearance in dogs.
| MATERIALS AND METHODS

| Data acquisition and analysis
The medical records of dogs which had samples submitted for GFR estimation by serum iohexol clearance to the Royal Veterinary College (RVC) GFR/therapeutic drug monitoring service from March 9, 2012, to November 4, 2017, were assessed. The project was reviewed and approved by the RVC clinical research and ethical review board, which allowed access to joint iohexol clearance test submission forms held by deltaDOT Ltd and the RVC. Additionally, contact with the veterinarians for access to the clinical records of the dogs under investigation and for completion of a short questionnaire regarding outcomes was approved. This contact was performed before the final implementation of the General Data Protection Regulation (EU) 2016/679.
| Iohexol clearance protocol
A standard protocol was recommended to veterinarians collecting samples to be submitted for measurement of iohexol clearance. Dogs were well hydrated at the time of the test, had free access to water for 12 hours before testing, and had no clinical signs consistent with dehydration or hypovolemia. Food was withheld for 12 hours before testing. A single dose of iohexol (Omnipaque 300) was administered at 300 mg iodine/kg IV through a catheter. The IV catheter was then flushed with saline. Blood was collected into serum gel tubes precisely at 2, 3, and 4 hours after iohexol administration. Exact times of blood collection and iohexol administration were noted, and if there were discrepancies with the protocol, the actual time between dose administration and sampling was used in the calculation. Blood was centrifuged after clotting as per the centrifuge manufacturers' instructions for separation of serum. The serum samples were shipped at room temperature for next day delivery. Serum iohexol concentration for each serum sample was measured using deltaDOT Ltd's validated high-performance capillary electrophoresis method. 25 To correct for any variability in the amount of sample injected onto the column, 3 μL of iopromide was added to 57 μL of each sample (2-, 3-, and 4-hour post-iohexol serum samples) as an internal standard and this was used to correct the iohexol concentrations for variation in sample volume applied to the system. Data were analyzed using deltaDOT Ltd's generalized separation transform.
Serum iohexol concentrations were used to calculate serum clearance of iohexol. Glomerular filtration rate was estimated from the serum clearance of iohexol by application of a compartmental model and canine-specific correction formula, 22 22 In the event that a dog's body weight did not fall within the range of 1 of these body weight categories, the dog was included in the body weight category to which its body weight was closest.
The estimated GFR of each dog was compared with the expected mean GFR of their respective body weight categories: 2.89 mL/kg/min for Category 1, 2.4 mL/kg/min for Category 2, 2.16 mL/kg/min for Category 3, and 2.25 mL/kg/min for Category 4. 22 where in addition there was at least 1 measurement of creatinine from the submitting veterinarian that had been ≥0.3 mg/dL above their specific laboratory reference interval with concurrent USG <1.030, which was considered consistent with CKD. One dog with a serum creatinine concentration that was 0.54 mg/dL above the upper end of the reference interval with concurrent USG of 1.013 was included in Group A1 rather than in Group A2 as it was a Greyhound, a breed that has higher serum creatinine concentrations than other dog breeds. 26 For classification into Groups A1 and A2, clinical changes were required to be present for >1 month indicating chronicity. Group B included those dogs in which there was suspicion for an AKI based on historical findings and duration of clinical signs being <1 month, and included screening for cutaneous and renal glomerular vasculopathy (CRGV) in cases that presented with unexplained skin lesions. 27 Dogs not falling into Groups A1, A2, or B were considered miscellaneous (Group C).
| Clinical case data collection
| Case classification
Glomerular filtration rate estimation results from individual dogs in Groups A1, A2, and B were interpreted using categories of: GFR Group 1: GFR increased or <20% decreased from the mean GFR of the body weight category, kidney disease considered excluded or unlikely as a cause of presenting clinical signs; GFR Group 2: ≥20% but <30% decrease in GFR from the mean GFR of the body weight category, kidney disease considered possible but unconfirmed as an etiology for presenting clinical signs; GFR Group 3: ≥30% but <40% decrease in GFR from the mean GFR of the body weight category, kidney disease considered likely as an etiology for presenting clinical signs; and GFR Group 4: ≥40% decrease in GFR from the mean GFR of the body weight category, kidney disease considered almost certain as an etiology for presenting signs. The criterion for GFR Group 1 was based on the anticipated variability in iohexol clearance measurement where the within individual variability for GFR estimation via iohexol clearance has previously been reported as 19.9% for non-azotemic cats. 28 Criteria for Categories 3 and 4 were based on estimates of GFR reduction that have been associated with the point at which serum creatinine becomes elevated in previous studies. 29 
| Statistical analysis
| Clinical case evaluation
Dogs were categorized based on presenting reason for GFR assessment before further analysis; Group A1, n = 105; Group A2, n = 3;
Group B, n = 19; and Group C, n = 5. Clinical signs, signalment, and laboratory findings for dogs based on reason for presentation groups are presented in Tables 2 and 3 Table 3 . A full list of the tests performed before GFR estimation in dogs in Groups A1, A2, B, and C is provided in Supplemental Table 1 .
A total of 47 (35.6%) dogs across Groups A1-C were receiving medications at the time of GFR estimation. Of these, 18 were receiving medications that could influence GFR (angiotensin-converting enzyme-inhibitors n = 9, glucosamine n = 3, levothyroxine n = 3, angiotensin-receptor antagonist n = 1, prednisolone n = 1, and topical prednisolone n = 1). Details on drugs being administered at the time of GFR estimation in each group are presented in Table S2 .
| Evaluation of outcome data: Group A1
| Diagnosis
In Group A1, follow-up data were available for 79 cases and on review of this information a final diagnosis was reached in 77% (61/79).
Overall, the most common diagnoses reached in Group A1 were psy- 
| Development of azotemia
Of the 103 dogs in Group A1 for which serum creatinine was available at the time of GFR estimation, 23 (22%) dogs had azotemia documented before GFR estimation, whereas 80 (78%) dogs were not azotemic. In 18 of the 23 azotemic cases, the azotemia was considered borderline, that is, ≤0.3 mg/dL above the upper end of the laboratory Abbreviations: UPC, urine protein-to-creatinine ratio; USG, urine specific gravity.
| Status
Data pertaining to status was available for 83 (79%) dogs in Group A1. In Group A2, follow-up data were available for 2 of 3 cases. All 3 dogs in Group A2 were assessed to have been diagnosed with CKD before GFR estimation on the basis of overt azotemia (creatinine 2.0, 1.76, and 1.78 mg/dL), and follow-up data confirmed the diagnosis of CKD in both dogs for which these data were available. Glomerular filtration rate categorization for Group A2 showed that in 1 dog, GFR was reduced by ≥30% but <40%, and in 2 dogs ≥40% commensurate with their documented azotemia. Both dogs for which follow-up data were available were alive at the time of follow-up. 
Sixty
| Development of azotemia
Three out of 19 dogs in Group B had azotemia documented before GFR estimation, whereas the remaining 16 dogs in Group B were not azotemic. In all 3 azotemic cases, the azotemia was considered borderline, that is, <0.3 mg/dL above the upper end of the laboratory reference interval for creatinine. No dogs in Group B developed azotemia during the follow-up period.
| Status
All 15 dogs for which follow-up data were available were alive at the time of follow-up and none had gone on to develop progressive CKD.
| Evaluation of outcome data: Group C
Glomerular filtration rate categorization for Group C showed that in 1 dog GFR was reduced by <20%, in 1 dog GFR was reduced by ≥30% but <40%, and in 1 dog ≥40%. Follow-up data pertaining to whether or not carboplatin dose was adjusted based on GFR estimation was only available for 1 of 3 dogs. This dog had a 19% reduction in GFR from the mean of its body weight category and did not have carboplatin dose adjusted. Follow-up data pertaining to status were available for all 3 dogs. Two dogs were dead and 1 was alive at the time of follow-up. Of the 2 dead dogs, 1 was euthanized because of metastatic colonic adenocarcinoma 288 days after GFR estimation.
The date and cause of death of the other dog was unknown.
| DISCUSSION
This study demonstrates the clinical utility of GFR estimation in dogs.
In Group A1 for which GFR estimation was performed for suspicion of pre-azotemic CKD, using our preliminary categorization criteria, F I G U R E 3 Distribution of dogs in Group B (glomerular filtration rate [GFR] estimation performed to screen for pre-azotemic acute kidney injury) and documented outcome 100% of dogs in GFR Group 4, 83.3% of dogs in GFR Group 3, and 77.8% of dogs in GFR Group 2 (for which final diagnoses were available) were ultimately diagnosed with a renal etiology of their clinical signs or laboratory findings that prompted GFR estimation. These results suggest that the decline in GFR is detectable before the onset of azotemia in this subgroup of dogs, with GFR estimation therefore contributing to the diagnostic investigation. Relatively few (n = 6) dogs had SDMA measurements performed by their local veterinarian; therefore, based on the data provided, it was impossible to determine whether SDMA would have indicated reduced renal function in these dogs where creatinine concentration had not done so.
One dog in each of GFR Groups 2 and 3 (GFR reduction of ≥20% but <30% and ≥30% but <40%, respectively) was considered clinically normal by the submitting veterinarians at the time of follow-up.
Unfortunately, this assessment was based on spontaneous resolution of the dogs' clinical signs (polyuria-polydipsia in both cases) rather than on longitudinal monitoring of their kidney function. Therefore, the authors cannot exclude the possibility that these dogs had undetected kidney disease at the time of follow-up, and that progression of kidney disease could have been documented either through serial assessment of serum creatinine concentration or repeat GFR estimation. The ultimate classification of these dogs as normal can therefore be questioned.
Other possible explanations were that the GFR estimation results in these 2 dogs were erroneous, or that the dogs did indeed have CKD but had a transient GFR reduction that later returned to normal; after the loss of nephrons, the kidney adapts via hyperfiltration of the remaining nephrons. 30, 31 This compensatory response could have led to a return of GFR back forwards normal and a subsequent resolution in clinical signs.
A range of diagnoses were obtained in dogs in Group A1 that demonstrated an increase or up to 20% reduction in their GFR value (GFR Group 1). However, in 5 of the 37 (14%) dogs in this GFR category for which a final diagnosis was available, a renal etiology of the dog's clinical signs was ultimately obtained (PLN, n = 2; idiopathic renal hematuria, n = 1; progressive CKD, n = 1; and pyelonephritis, n = 1). This study has multiple limitations. First, the study was retrospective in nature and the study population was relatively small. Submissions came from many different practices, including referral centers and general practices. There is therefore inherent variation in the extent and quality of the diagnostic investigation that was performed in dogs before and after GFR estimation. This led to difficulties in The authors acknowledge that using breed-specific reference ranges for creatinine or serial monitoring of creatinine concentrations could increase the sensitivity of creatinine for detection of CKD or AKI. Given that creatinine values for this study came from many different laboratories using different reference intervals, comparing the sensitivity of GFR estimation for the detection of pre-azotemic CKD or AKI to the use of breed-specific creatinine reference intervals or serial creatinine measurements was not possible. Such a comparison could be a focus for future study. Future studies are also required to compare the clinical utility of GFR estimation for detecting pre-azotemic CKD and AKI to other biomarkers, for example, SDMA which was infrequently available in this population of dogs. Longer term studies would be required to better evaluate the predictive capacity of GFR estimation for the future development of azotemic CKD.
In conclusion, in our population of dogs, GFR estimation via iohexol clearance was useful for the diagnosis of CKD before the onset of azotemia and for ruling out pre-azotemic AKI. In dogs that already had a diagnosis of azotemic CKD, GFR estimation provided no additional diagnostic benefit. Based on data from previous publications, 32 GFR estimation is also useful to screen for the need for carboplatin dose adjustment in dogs undergoing chemotherapy, although it was not possible to determine the clinical utility of GFR estimation for this purpose in our study because of lack of follow-up data from this subset of dogs. The clinical utility of GFR estimation must be balanced against the theoretical risk for iohexol administration to contribute to an AKI. 33 ACKNOWLEDGMENT An abstract of this paper was presented at the 28th ECVIM Congress in Rotterdam, the Netherlands, in September 2018.
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